NCT05479422 is a clinical trial in Anterior Urethral Stricture, Male, sponsored by European Association of Urology Research Foundation.

Who is sponsoring NCT05479422?

NCT05479422 is sponsored by European Association of Urology Research Foundation.

What condition does NCT05479422 study?

NCT05479422 studies Anterior Urethral Stricture, Male.

Is NCT05479422 still recruiting?

NCT05479422 is currently active, enrolled. Last updated 24 February 2025.

Last reviewed 2025-02-24 · How we verify

NCT05479422

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optilume Registry for Treatment of Stricture of the Anterior Urethra

Active, enrolled Last updated 24 February 2025

What this trial tests

trial in Anterior Urethral Stricture, Male in 150 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

13 October 2022

Primary endpoint
15 August 2029

15 August 2029

Quick facts

Lead sponsor	European Association of Urology Research Foundation
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	150
Start date	13 October 2022
Primary completion	15 August 2029
Estimated completion	15 August 2029
Sites	13 locations across Italy, Belgium, United Kingdom, Norway, Spain

Conditions studied

Anterior Urethral Stricture, Male — all drugs for Anterior Urethral Stricture, Male →

Sponsor

European Association of Urology Research Foundation

Who can join

18 and older, male only, with Anterior Urethral Stricture, Male. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this registry is verifying the continued safety and effectiveness of the Optilume DCB clinical use in patients undergoing dilation of the urethral stricture.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Optilume, a minimally invasive solution for BPH and urethral stricture: what we know, what we need? an EAU endourology scoping review.
Gauhar V, Yuen SKK, Gadzhiev N, Wroclawski M, et al · · 2025 · cited 1× · PMID 40783764 · DOI 10.1186/s12894-025-01896-3
Optilume® for Urethral Strictures: A Comprehensive Review.
Carmali D, Ramos S, Duarte S, Felício E, et al · · 2025 · PMID 40416173 · DOI 10.7759/cureus.82984

Verify or expand the search:

Other European Association of Urology Research Foundation trials

Trials by the same sponsor.

NCT06424275 — Prostate Cancer Awareness and Initiative for Screening in the European Union · enrolling by invitation
NCT04294277 — Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery · Phase 2 · terminated
NCT04114266 — Registry for Patients Undergoing AUS Surgery for Female SUI Due to ISD · active not recruiting
NCT03665467 — The Global Prevalence of Infections in Urology Study · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05479422 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by European Association of Urology Research Foundation
Last refreshed: 24 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05479422.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing